|Wednesday, June 14, 2017|
|Add to Calendar|
|1:00 PM Eastern||12:00 PM Central|
|11:00 AM Mountain||10:00 AM Pacific|
Immunotherapy is an exciting and rapidly growing field in multiple myeloma treatment. Two new immunotherapy drugs (monoclonal antibodies) have been approved for patients with relapsed or refractory myeloma, and others have shown promise in later-stage clinical trials and may be approved soon. To be the best advocates they can be for their own care, myeloma patients need to understand how immunotherapy works, what makes this new treatment approach different, and what patients who receive it can expect. Our new webinar series will address these aspects of immunotherapy, and much more.
Two convenient ways to participate:
- By phone